Skip to main content

Table 4 Summary of DVH-based analysis for the bladder in five groups

From: Escalation of radiotherapy dose in large locally advanced drug-resistant gastrointestinal stromal tumors by multi-shell simultaneous integrated boost intensity-modulated technique: a feasibility study

Groups

V20(%)

V30(%)

V40(%)

V50(%)

D1cc (cGy)

D2cc (cGy)

Dmean(cGy)

EUDbla(cGy)

Con-IMRT

96.10

(77.90–100.0)

76.10

(42.00–97.10)

43.42

(15.70–66.32)

11.50

(0.90–31.90)

5154.12

(5010.90–5246.00)

5088.70

(4966.30–5207.70)

3747.82

(3064.30–4360.10)

36.14

(28.11–42.96)

SIB10-IMRT

93.95

(67.20–100.0)

75.25

(41.70–95.70)

40.83

(15.20–64.76)

8.79

(0.70–26.20)

5147.27

(5003.20–5418.50)

5102.40

(4923.50–5335.80)

3663.87

(3020.60–4304.50)

35.28

(27.57–42.32)

SIB15-IMRT

91.23

(70.40–100.0)

74.02

(35.80–95.30)

41.39

(12.90–64.91)

9.43

(1.20–28.30)

5208.35

(5044.00–5505.10)

5147.88

(4971.00–5416.00)

3652.37

(2817.30–4340.40)

35.20

(25.95–42.81)

SIB20-IMRT

96.33

(79.90–100.0)

77.75

(51.10–97.00)

43.28

(13.20–65.28)

9.36

(0.70–31.40)

5197.47

(5000.40–5435.70)

5128.37

(4927.60–5370.40)

3755.48

(3146.60–4378.60)

36.03

(28.39–43.26)

SIB25-IMRT

96.82

(81.30–100.0)

82.78

(65.50–99.40)

44.89

(16.40–67.25)

9.89

(1.00–30.60)

5225.93

(5027.20–5432.70)

5153.85

(4961.40–5375.60)

3833.98

(3348.70–4386.40)

36.76

(30.44–43.28)

p-values

0.293

0.139

0.053

0.033*

0.220

0.066

0.034**

0.043***

  1. Bold represented the optimal values of parameters. It displayed the trend of each parameter more plainly
  2. EUDbla: the EUD of bladder
  3. *The lowest p-value of Pairwise comparisons for V50 (%): Con-IMRT VS SIB10-IMRT, P = 0.081
  4. **The significant differences of Pairwise comparisons for Dmean: SIB10-IMRT VS SIB25-IMRT, P = 0.019
  5. ***The significant differences of Pairwise comparisons for EUDbla: SIB10-IMRT VS SIB25-IMRT, P = 0.035